Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Eva Blondeaux contribution to redefining risk in HR+/HER2− early breast cancer

    We are pleased to highlight the contribution of Dr. Eva Blondeaux to the latest publication in the Journal of the National Cancer Institute (published February 5, 2025), titled:“Prognostic implications of…

    2025.04.10
  • Tracking Molecular Shifts in High-Risk Luminal Breast Cancer: Insights from the Penelope-B Trial

    Published on February 10, 2025, in Cancer Cell, this international effort led by Carsten Denkert and colleagues investigates the dynamics of therapy-induced molecular heterogeneity in high-risk HR+/HER2− breast cancer, using…

    2025.04.10
  • Professor Aiwen Wu:Should a “Watch and Wait” Approach Be Considered Before Treating Low Rectal Cancer?    | Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee

    In the treatment of low rectal cancer, the “watch and wait” strategy has sparked a compelling debate between organ preservation and radical resection. With the advancement of neoadjuvant therapies, some patients achieve clinical complete response (cCR) following chemoradiotherapy, opening the door to non-operative management and the possibility of avoiding a permanent stoma. However, concerns over…

    2025.04.09
  • JGCA 2025 | Professor Bo Wei: Two Key Future Directions for Neoadjuvant Therapy in Locally Advanced Gastric Cancer—“Precision and Minimally Invasive Approaches”

    From March 12 to 14, 2025, the 97th Annual Meeting of the Japanese Gastric Cancer Association (JGCA 2025) was held at the Nagoya Congress Center, bringing together leading experts from Japan and across the globe to exchange insights on the latest advancements in gastric cancer prevention and treatment. The event also spotlighted the application and…

    2025.04.09
  • JGCA 2025 | Professor Yanbing Zhou: Robot-Assisted Surgery Significantly Improves Clinical Outcomes for Obese Gastric Cancer Patients (Part 2)

    3. Robotic Gastrectomy: More Suitable for Viscerally Obese Gastric Cancer Patients Obesity and metabolic syndrome in gastric cancer patients have become a pressing clinical issue. As global obesity rates continue…

    2025.04.09
  • Professor Chaoxu Zheng: Non-Invasive, Painless Surgery That Preserves Dignity—The Ultimate Goal in Colorectal Cancer Surgery   | Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee

    From February 28 to March 1, 2025, the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee was held in Beijing. This year’s meeting focused on the standardization, precision, and personalization of colorectal cancer diagnosis and treatment, drawing top experts from China and around the world to explore the latest advances in…

    2025.04.09
  • JGCA 2025 | Professor Yanbing Zhou : How Minimally Invasive Techniques and Innovative Thinking Are Reshaping the Future of Gastric Cancer Treatment

    1. Robotic Gastrectomy Poised to Enhance Clinical Outcomes in Gastric Cancer Patients Undergoing Neoadjuvant Therapy This year’s International Session at the JGCA 2025—titled “Current Status and Perspectives of Digital Innovation…

    2025.04.09
  • JGCA 2025 | Professors Bo Wei & Zekuan Xu: Proteomic Analysis Ushers in a New Era of Precision Therapy in Gastric Cancer

    A study from the Chinese PLA General Hospital—focused on predicting the efficacy of neoadjuvant chemoimmunotherapy in gastric cancer using proteomic analysis—was selected for oral presentation (MO8-7) at the conference. Oncology…

    2025.04.09
«previous next»
Recent Posts
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
  • Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
  • Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top